Condition
Schizophrenia Clinical Trials
Studies of schizophrenia, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 559Schizophrenia
Phase I Trial of HHK101 in Patients With Schizophrenia
This study aims to learn how the study drug is absorbed by the body, check for possible side effects, and see if the drug may help improve symptoms in patients with schizophrenia.
- Trial name
- NCT07815210
- Testing
- HHK101-Single Dose 1, HHK101-Single Dose 2, HHK101-Single Dose 3
- Volunteers
- 88 people
- Sponsor
- Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
The goal of this pilot randomized controlled trial is to investigate whether the Integrated Psychoeducation Program reduces internalized stigma and improves related outcomes in adults with schizophrenia or schizoaffective…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Internalized Stigma, Social Stigma
- Trial name
- NCT07898852
- Testing
- Integrated Psychoeducation Program
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Dokuz Eylul University
Schizophrenia Spectrum Disorders
Non-Invasive Vagus Nerve Stimulation as a Probe to Map Functional Connectivity in Schizophrenia Using Functional Magnetic Resonance Imaging
The purpose of this study is to learn whether a handheld, non-invasive stimulation device called gammaCore Emerald can change brain activity and thinking skills.
- Trial name
- NCT07897266
- Testing
- nVNS (non-invasive vagal nerve stimulation)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Suicide, Mental Health Stigma
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
We will develop a mental health program, called RESTEPS, for patients with early psychosis being treated in outpatient mental health centers, focusing on reducing suicide risk by targeting mental health stigma and social support.
- Trial name
- AFSP RESTEPS (NCT07898631)
- Testing
- RESTEPS
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Butler Hospital
Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
- Trial name
- NCT06585787
- Testing
- KarXT
- Where
- 296 sites in United States, Argentina and 23 more
- Volunteers
- 406 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia Spectrum, Schizophrenia
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain.
- Conditions
- Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
- Trial name
- dTMS (NCT07795554)
- Testing
- dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
First Episose Psychosis, Metabolic Disease
The ATP Project (Antipsychotic-TEP-Psychosis)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
- Conditions
- First Episose Psychosis, Metabolic Disease, Psychosis; Episode
- Trial name
- ATP (NCT06651112)
- Testing
- Antipsychotic drugs
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Université de Sherbrooke
Psychotic Disorders, Family Members
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one.
- Conditions
- Psychotic Disorders, Family Members, Anosognosia, Paranoia
- Trial name
- NCT05500001
- Testing
- Supporting Patients by Family Education in Psychotic Illness Group
- Where
- 4 sites in Canada
- Volunteers
- 113 people
- Sponsor
- University of Alberta
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Schizophrenia Disorders
Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia
Schizophrenia, affecting 1% of the population, is a persistent disorder characterized by varied symptoms. Antipsychotic medications effectively address positive symptoms (delusions, hallucinations) and relapse but have limited…
- Trial name
- ARCoS-2 (NCT07055204)
- Testing
- "Diapason & Metronome" musical learning
- Where
- 6 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Toulouse
Completed, with results posted
All 744First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Psychosis
Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation
The overall aim of the proposed study is to determine the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted nurse-led, community-based rehabilitation treatment model for community-dwelling…
- Trial name
- ENHANCE (NCT06080477)
- Testing
- Enhanced Usual Care, Adapted ENHANCE Intervention
- Where
- Malawi
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill